The FDA was asked recently by the House Energy and Commerce Committee to turn over the results of the so-called Seas study from Oxford University. The results of this study shocked the medical society as well as investors.
The researchers from Oxford University found that risk of cancer in a group of patients taking Vytorin was unexpectedly higher than in the control group. And yet when the FDA submitted the results, it stated that the link between Vytorin and higher cancer risks wasn’t there. Funny though, how the study was submitted to the FDA but never to the House Commerce Committee, which investigates the safety of prescription drugs.
So, can we fully trust the FDA? It seems the answer is obvious.
health, Vytorin, cancer
Technorati Tags: health, Vytorin, cancer
You may also find interesting
This entry was posted on Saturday, August 2nd, 2008 at 4:38 pm and is filed under Do you know, General health. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.
Is the FDA Really Watching What’s In Our Supplements?
Melatonin may be beneficial for cancer prevention
Why you may be at higher risk for loosing your uterus, then European women
Can Losing Weight Protect You From Cancer
Women Prefer Shopping Over Sex
Diesel Exhaust Can Promote Heart Disease
Exposure to Second Hand Smoke Found To Increase Cancer Risk
Excessive Estrogen May Cause Problems Passing Urine in Men
Menopause management: what you need to know about osteoporosis
Do we need hormone replacement therapy for menopause treatment?
Menopause and Sex Drive
New Study Gives Us A Cancer Prevention Tip
Menopause And Brain Health
Do We Need Statins At All?
How To Easily Check Your Estrogen Levels
Bioidentical stimulators for rejuvenation
UTI’s Can Be Treated With Hormones
Light can save your life, light can kill you
Secret complications of plastic surgery and how to avoid them
What Can Be Done About Droopy Breasts